**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**

**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**

Lupus

#LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus #patientstory #SLE

    In June 2024, 13-year-old Qingqing experienced a major turning point in her life. A year after being diagnosed with systemic lupus erythematosus (SLE), she received innovative CAR-T therapy at Shanghai Children’s Medical Center and successfully achieved disease remission. SLE, often referred to as the “incurable cancer,” is an autoimmune disease that affects millions of people worldwide, severely damaging the brain, lungs, kidneys, and blood system. Even when not in an acute flare, patients often suffer from chronic symptoms such as fatigue, rashes, pain, and fever.

    Qingqing’s treatment marks a significant breakthrough in the global fight against SLE. Previously, SLE patients could only rely on lifelong medications, such as steroids and immunosuppressants, to control the disease and prevent severe complications. However, these drugs often come with side effects and long-term organ damage. Qingqing’s case has offered the world new hope. A team led by Dr. Li Benshang, chief physician of the Hematology and Oncology Department, and Dr. Yin Lei, head of the Nephrology Department, pioneered the use of CAR-T therapy in SLE treatment and initiated a clinical study. After just two months of treatment, Qingqing’s condition has fully gone into remission, and all medications were discontinued.

    CAR-T therapy was originally used in cancer treatment by extracting a patient’s T cells and genetically modifying them to recognize and kill abnormal cells in the body. In the treatment of SLE, CAR-T therapy eliminates the abnormal plasma cells producing autoantibodies, effectively “resetting” the patient’s immune system and addressing the root cause of the disease.

    Qingqing’s success story is not only a milestone in China’s CAR-T technology but also a major leap forward in the global treatment of autoimmune diseases like SLE. Since the first CAR-T treatment cured an SLE patient in 2021, numerous clinical trials have been conducted worldwide, and several Chinese hospitals have also achieved success. However, while early results are encouraging, further research and validation are needed to confirm the long-term safety and efficacy of the treatment.

    With 20% of the global population affected by various types of autoimmune diseases, CAR-T therapy holds the potential to bring new life to millions of patients. China’s ongoing research and international collaboration in this field offer unprecedented hope for overcoming persistent diseases like SLE.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

 (Https://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com

#CAR-Ttherapy #LupusTreatment #AutoimmuneDisease #MedicalInnovation #ChinaHealthcare #Immunotherapy #CancerTreatment #HealthBreakthrough #HopeForLupus #FutureOfMedicine